此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

ALZ-801 在 APOE4/4 早期 AD 受试者中的疗效和安全性研究 (APOLLOE4)

2026年9月3日 更新者:Alzheon Inc.

ALZ-801 对患有早期阿尔茨海默病和 APOE4/4 基因型的受试者的疗效、安全性和生物标志物效应的 3 期、多中心、随机、双盲、安慰剂对照研究

This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo.

研究概览

详细说明

This is a multi-center, double-blind study that will evaluate 265 mg twice daily (BID) of ALZ-801, an oral tablet, over 78 weeks as a treatment for subjects (50-80 years old) with Early AD who are homozygous for the ε4 allele of the apolipoprotein gene (APOE4 homozygous or APOE4/4). The primary efficacy outcome assessment is a measure of cognition (ADAS-cog 13). Additional measures of global and functional impairments will also be assessed. Imaging and soluble biomarkers of AD and neurodegeneration will be measured and a sub-study to evaluate cerebrospinal fluid (CSF) biomarkers is also included.

研究类型

介入性

注册 (实际的)

325

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Reykjavik、冰岛、101
        • Memory Clinic, Landspitali University Hospital
    • British Columbia
      • Kelowna、British Columbia、加拿大、V1Y 1Z9
        • OCT Research ULC (dba Okanagan Clinical Trials)
    • Nova Scotia
      • Halifax、Nova Scotia、加拿大、B3S 1N2
        • Centricity Research
      • New Minas、Nova Scotia、加拿大、B4N 3R7
        • Centricity Research
    • Ontario
      • Ottawa、Ontario、加拿大、K1Z 1G3
        • Recherches Neuro-Hippocampe Inc., d/b/a Ottawa Memory Clinic
      • Peterborough、Ontario、加拿大、K9H 2P4
        • Kawartha Centre - Redefining Healthy Aging
      • Toronto、Ontario、加拿大、M3B 2S7
        • Toronto Memory Program
    • Quebec
      • Gatineau、Quebec、加拿大、J8T 8J1
        • Recherches Neuro-Hippocampe Inc. d/b/a Clinique de la Mémoire de l'Outaouais
      • Aachen、德国、52074
        • University Hospital RWTH Aachen Neurological Study Center
      • München、德国、80336
        • Klinikum der Universitaet Muenchen Innenstadt
      • Tübingen、德国、72076
        • Universitätsklinik fuer Psychiatrie und Psychotherapie
      • Westerstede、德国、26655
        • Studienzentrum Nord-West
      • Brno、捷克语、656 91
        • Fakultní nemocnice u sv. Anny v Brně (St. Anne's University Hospital)
      • Brno、捷克语、602 00
        • Medica 111, Spol. s r.o. - Neurologicka a Rehabilitacni Ambulance Brno, Centralni Pracoviste v Brne
      • Prague、捷克语、160 00
        • Neuropsychiatrie s.r.o.
      • Rychnov nad Kněžnou、捷克语、51601
        • Vestra Clinics - Dedicated Research Clinics
      • Marseille、法国、13385
        • Centre Hospitalier Universitaire de Marseille - Hôpital de la Timone
      • Montpellier、法国、43431
        • Hopital Gui de Chauliac - CHRU de Montpellier
      • Paris、法国、75475
        • Hopital Lariboisiere - Fernand-Widal - AP-HP
      • Rouen、法国、76031
        • Centre Hospitalier Universitaire (CHU) Hopitaux de Rouen
      • Strasbourg、法国、67200
        • Hopitaux Universitaires de Strasbourg Centre d'Investigation Clinique
      • Toulouse、法国、31059
        • Centre de Recherche Clinique du Gerontopole - CHU Toulouse
      • Villeurbanne、法国、69100
        • Centre de Recherche-Hopital Geriatrique de Charpennes
    • Arizona
      • Phoenix、Arizona、美国、85004
        • Xenoscience
      • Scottsdale、Arizona、美国、85297
        • CCT Research
      • Sun City、Arizona、美国、85351
        • Banner Sun Health Research Institute
    • California
      • Costa Mesa、California、美国、92626
        • ATP Clinical Research
      • Irvine、California、美国、92780
        • Tilda Research
      • La Jolla、California、美国、92037
        • UCSD Shiley-Marcos Alzheimer's Disease Research Center
      • Lomita、California、美国、90717
        • Torrance Clinical Research Institute
      • Long Beach、California、美国、90806
        • Collaborative NeuroScience Network LLC
      • Palo Alto、California、美国、94304
        • Stanford University
      • Pasadena、California、美国、91105
        • SC3 Research Group
      • Sacramento、California、美国、95816
        • Sutter Health
    • Florida
      • Atlantis、Florida、美国、33462
        • JEM Research Institute, Headlands Site
      • Bradenton、Florida、美国、34205
        • Bradenton Research Center
      • Hialeah、Florida、美国、33016
        • Galiz Research
      • Jupiter、Florida、美国、33458
        • Alphab Global Research
      • Lady Lake、Florida、美国、32159
        • Charter Research
      • Maitland、Florida、美国、32751
        • K2 Medical Research, LLC
      • Miami、Florida、美国、33137
        • Miami Jewish Health
      • Miami、Florida、美国、33144
        • Y & L Advance Health Care, Inc /DBA Elite Clinical Research
      • Miami Beach、Florida、美国、33140
        • Mount Sinai Medical Center
      • Naples、Florida、美国、34105
        • Aqualane Clinical Research
      • Orlando、Florida、美国、32819
        • Headlands Research Orlando
      • Orlando、Florida、美国、32803
        • Charter Research
      • Palm Beach Gardens、Florida、美国、33410
        • Advanced Research Consultants
      • Pompano Beach、Florida、美国、33064
        • Quantum CNS Clinical Research
      • Port Orange、Florida、美国、32127
        • Progressive Medical Research
      • Stuart、Florida、美国、34997
        • ALZ Research and Treatment Center (A.R.T.C.)
      • Wellington、Florida、美国、33414
        • ALZ Research and Treatment Center (A.R.T.C.)
      • West Palm Beach、Florida、美国、33407
        • Premiere Research Institute
    • Georgia
      • Columbus、Georgia、美国、31909
        • Columbus Memory Center
      • Decatur、Georgia、美国、30030
        • Sandhill Research, LLC
    • Indiana
      • Fort Wayne、Indiana、美国、46804
        • Fort Wayne Neurological Center
    • Louisiana
      • Shreveport、Louisiana、美国、71103
        • Louisiana State University Health Sciences Center (LSUHSC)
    • Massachusetts
      • Plymouth、Massachusetts、美国、02360
        • Headlands Research Eastern MA
    • Nevada
      • Las Vegas、Nevada、美国、89106
        • WR-CRCN
    • New Jersey
      • Toms River、New Jersey、美国、08755
        • Advanced Memory Research Center
    • New York
      • Albany、New York、美国、12208
        • Neurological Associates of Albany
      • New York、New York、美国、10016
        • NYU Alzheimer's Disease Research Center
      • Orangeburg、New York、美国、10962
        • Kline Institute for Psychiatric Research
      • Rochester、New York、美国、14620
        • University of Rochester Medical Center
      • Staten Island、New York、美国、10312
        • Richmond Behavioral Associates
    • North Carolina
      • Greensboro、North Carolina、美国、27410
        • Triad Clinical Trials
      • Matthews、North Carolina、美国、28105
        • AMC Research
    • Ohio
      • Canton、Ohio、美国、44718
        • NeuroScience Research Center
      • Dayton、Ohio、美国、45459
        • Neurology Diagnostics, Inc.
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73106
        • IPS Research
    • Oregon
      • Portland、Oregon、美国、97225
        • Center for Cognitive Health
    • Pennsylvania
      • Abington、Pennsylvania、美国、19001
        • Abington Neurological Associates
      • Allentown、Pennsylvania、美国、18104
        • Lehigh Center for Clinical Research
    • Rhode Island
      • East Providence、Rhode Island、美国、02914
        • Rhode Island Mood & Memory Research Institute
    • Tennessee
      • Nashville、Tennessee、美国、37212
        • Vanderbilt Center for Cognitive Medicine
    • Texas
      • Houston、Texas、美国、77054
        • UT Health Science Center at Houston
    • Virginia
      • Fairfax、Virginia、美国、22031
        • Re:Cognition Health
    • Washington
      • Bellevue、Washington、美国、98007
        • Northwest Clinical Research Center
    • Wisconsin
      • Milwaukee、Wisconsin、美国、53226
        • Medical College of Wisconsin
      • Bristol、英国、BS32 4SY
        • Re:Cognition Health Ltd Bristol
      • London、英国、EC2Y 8EA
        • St. Pancras Clinical Research
      • Winchester、英国、SO21 1HU
        • Re-Cognition Health Ltd Winchester
    • Devon
      • Plymouth、Devon、英国、PL6 8BT
        • Re-Cognition Health Ltd Plymouth
    • Greater London
      • London、Greater London、英国、W1G 9JF
        • Re-Cognition Health Ltd London
    • North Lanarkshire
      • Motherwell、North Lanarkshire、英国、ML1 4UF
        • NeuroClin Glasgow Ltd
    • Surrey
      • Guildford、Surrey、英国、GU2 7YD
        • Re-Cognition Health Ltd Guildford
    • West Midlands
      • Birmingham、West Midlands、英国、B16 8LT
        • Re-Cognition Health Ltd Birmingham
      • 's-Hertogenbosch、荷兰、5223 LA
        • Brain Research Center Den Bosch
      • Amsterdam、荷兰、1081 GN
        • Brain Research Center Amsterdam
      • Zwolle、荷兰、8025 AZ
        • Brain Research Center Zwolle
      • Barcelona、西班牙、08028
        • Fundacia ACE - Institut Catala de Neurociencies Aplicadas
      • Madrid、西班牙、28040
        • Hospital Clinico San Carlos
      • Madrid、西班牙、28027
        • Clinica Universidad de Navarra
      • Pamplona、西班牙、31008
        • Clinica Universidad de Navarra
      • Terrassa、西班牙、08221
        • Hospital Universitari MutuaTerrassa
      • Valencia、西班牙、46017
        • Centro Hospital Universitario Dr. Preset

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Clinical diagnosis of MCI or Mild Dementia due to AD consistent with the National Institute on Aging-Alzheimer's Association (NIA-AA) Working Group Criteria.
  • Homozygous for the ε4 allele of the apolipoprotein E gene (APOE4/4).
  • MMSE score at Screening of 22 to 30 (inclusive).
  • CDR - Global score of 0.5 or 1 and CDR Memory Box Score of ≥ 0.5.
  • RBANS delayed memory index score ≤ 85.
  • Evidence of progressive memory loss over the last 12 months per investigator assessment

Exclusion Criteria:

  • Brain magnetic resonance imaging (MRI) indicative of significant abnormality per central reader, other than AD related atrophy. Computed tomography (CT) scan acceptable for subjects who cannot undergo MRI.
  • Diagnosis of neurodegenerative disorder other than AD.
  • Diagnosis of major depressive disorder (MDD) within one year prior to screening.
  • Currently taking memantine or has taken memantine within 12 weeks prior to the Baseline Visit.
  • History of suicidal behavior within one year prior to screening or has ongoing suicidal ideation.
  • History of seizures, excluding febrile seizures of childhood or a single distant seizure (> 5 years).
  • Medically confirmed history of recent cerebral infarct or transient ischemic attack within one year prior to screening.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:ALZ-801

ALZ-801 265 mg BID tablet orally. Subjects will receive placebo in the morning and one tablet of ALZ-801 265 mg tablet in the evening during the first two weeks of the study; thereafter, they will receive a 265 mg tablet twice daily (BID).

ALZ-801 tablet 265 mg once daily in the evening for the first 2 weeks, then ALZ-801 tablet 265 mg BID

其他名称:
  • 瓣膜
  • 曲霉前药

Placebo tablet BID

安慰剂比较:Placebo

Subjects in the placebo treatment arm will receive placebo tablets BID throughout the study

Placebo tablet BID

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Primary Cognitive Efficacy Endpoint (ADAS-Cog13)
大体时间:Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog13) scores.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
Incidence, Nature, and Severity of Treatment Emergent Adverse Events (TEAE)
大体时间:Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

Safety and tolerability as measured by incidence, nature and severity of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs leading to withdrawal.

Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

次要结果测量

结果测量
措施说明
大体时间
Key Secondary Endpoint (A-IADL-W)
大体时间:Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
Key Secondary Endpoint (CDR-SB)
大体时间:Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
Functional Assessment (DAD)
大体时间:Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Global Cognition Assessment (MMSE)
大体时间:Baseline to Week 78

Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills.

Baseline to Week 78

其他结果措施

结果测量
措施说明
大体时间
Imaging Biomarker Endpoint (Hippocampal Volume)
大体时间:Baseline to Week 78

Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration.

Baseline to Week 78
Imaging Biomarker Endpoint (Cortical Thickness [Whole Cortex])
大体时间:Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration.

Baseline to Week 78
Imaging Biomarker Endpoint (Cortical Thickness [Mayo Index])
大体时间:Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe.

Baseline to Week 78
Imaging Biomarker Endpoint (Whole Brain Volume)
大体时间:Baseline to Week 78

Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Imaging Biomarker Endpoint (Ventricular Volume)
大体时间:Baseline to Week 78

Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Imaging Biomarker Endpoint - DTI in Grey Matter Mean Diffusivity - Bilateral Caudate
大体时间:Baseline to Week 78

Change from baseline in Grey Matter Mean Diffusivity (Bilateral Caudate) as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). The mean diffusivity (MD) is the average of the three main diffusion values (eigenvalues) obtained from the diffusion tensor imaging (DTI). It is expressed as mm2/s. This unit quantifies the average rate of water diffusion across all directions within a tissue, providing an overall measure of tissue microstructural properties. Lower MD value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as lower mean diffusivity compared with the placebo group.

Baseline to Week 78
Imaging Biomarker Endpoint - DTI in White Matter Mean Diffusivity (Bilateral Fornix)
大体时间:Baseline to Week 78

Change from baseline in Bilateral Fornix White Matter Mean Diffusivity as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). The mean diffusivity (MD) is the average of the three main diffusion values (eigenvalues) obtained from the diffusion tensor imaging (DTI). It is expressed as mm2/s. This unit quantifies the average rate of water diffusion across all directions within a tissue, providing an overall measure of tissue microstructural properties. Lower MD value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as lower mean diffusivity compared with the placebo group.

Baseline to Week 78
Imaging Biomarker Endpoint - White Matter Fractional Anisotropy (Bilateral Fornix)
大体时间:Baseline to Week 78

Change from baseline in Bilateral Fornix White Matter Fractional Anisotropy as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). Fractional anisotropy (FA) is a unitless, scalar value that measures the degree of anisotropic (directional) water diffusion within a voxel, ranging from 0 to 1. A value of 0 indicates perfectly isotropic (equal in all directions) diffusion, while a value of 1 indicates perfectly anisotropic (directional) diffusion. Higher FA value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as higher FA in the ALZ-801 group compared with the placebo group.

Baseline to Week 78
Cognitive Efficacy Endpoint (ADAS-Cog 13) - MCI Subgroup
大体时间:Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Mild Alzheimer's Disease(Mild AD) Subgroup
大体时间:Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
A-IADL-W - MCI Subgroup
大体时间:Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
A-IADL-W - Mild AD Subgroup
大体时间:Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
CDR-SB - MCI Subgroup
大体时间:Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
CDR-SB - Mild AD Subgroup
大体时间:Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
Functional Assessment (DAD) - MCI Subgroup
大体时间:Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Functional Assessment (DAD) - Mild AD Subgroup
大体时间:Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Global Cognition Assessment (MMSE) - MCI Subgroup
大体时间:Baseline to Week 78

Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills.

Baseline to Week 78
Global Cognition Assessment (MMSE) - Mild AD Subgroup
大体时间:Baseline to Week 78

Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills.

Baseline to Week 78
Hippocampal Volume (MCI Subgroup)
大体时间:Baseline to Week 78

Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration.

Baseline to Week 78
Hippocampal Volume (Mild AD Subgroup)
大体时间:Baseline to Week 78

Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration.

Baseline to Week 78
Cortical Thickness (Whole Cortex) (MCI Subgroup)
大体时间:Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration.

Baseline to Week 78
Cortical Thickness (Whole Cortex) (Mild AD Subgroup)
大体时间:Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration.

Baseline to Week 78
Cortical Thickness (Mayo Index) (MCI Subgroup)
大体时间:Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe versus the whole cortex.

Baseline to Week 78
Cortical Thickness (Mayo Index) (Mild AD Subgroup)
大体时间:Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe versus the whole cortex.

Baseline to Week 78
Whole Brain Volume (MCI Subgroup)
大体时间:Baseline to Week 78

Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Whole Brain Volume (Mild AD Subgroup)
大体时间:Baseline to Week 78

Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Ventricular Volume (MCI Subgroup)
大体时间:Baseline to Week 78

Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Ventricular Volume (Mild AD Subgroup)
大体时间:Baseline to Week 78

Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Female Subgroup of the FAS
大体时间:Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Male Subgroup of the FAS
大体时间:Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
A-IADL-W - Female Subgroup
大体时间:Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
A-IADL-W - Male Subgroup
大体时间:Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
CDR-SB - Female Subgroup
大体时间:Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
CDR-SB - Male Subgroup
大体时间:Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
Functional Assessment (DAD) - Female Subgroup
大体时间:Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Functional Assessment (DAD) - Male Subgroup
大体时间:Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Treatment Emergent Adverse Events (TEAE) - Females
大体时间:Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

Safety and tolerability as measured by incidence of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs experienced by at least 5% of participants in either treatment group

Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
Treatment Emergent Adverse Events (TEAE) - Males
大体时间:Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

Safety and tolerability as measured by incidence of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs experienced by at least 5% of participants in either treatment group

Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Susan Abushakra, MD、Alzheon Inc.

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年5月19日

初级完成 (实际的)

2024年5月29日

研究完成 (实际的)

2024年7月29日

研究注册日期

首次提交

2021年2月22日

首先提交符合 QC 标准的

2021年2月22日

首次发布 (实际的)

2021年2月25日

研究记录更新

最后更新发布 (实际的)

2026年9月29日

上次提交的符合 QC 标准的更新

2026年9月3日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • ALZ-801-AD301
  • R01AG065253 (美国 NIH 拨款/合同)
  • 2020-005755-20 (EudraCT编号)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅